Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
All patients will be in instructed to eat a therapeutic lifestyle diet and will receive
CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the
cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first
measure the effects of CP-690,550 on cholesterol levels and then the effects of adding
atorvastatin on those levels.